Xin Jing Bao·2025-12-25 11:17Core Viewpoint - The approval of Nemonapride Chloride (brand name: Kaijiele) by the National Medical Products Administration marks the first new mechanism treatment for schizophrenia in over 70 years, providing a significant advancement in the management of this chronic mental illness [1][2]. Group 1: Drug Approval and Mechanism - Nemonapride Chloride has been approved for the treatment of adult schizophrenia, representing a novel therapeutic option with a unique mechanism of action [1]. - Unlike existing antipsychotic medications that primarily target dopamine or serotonin receptors, Nemonapride Chloride acts as a combination of M1/M4 muscarinic acetylcholine receptor agonist and antagonist, which may lead to improved efficacy and reduced side effects [2]. Group 2: Clinical Significance - The drug has shown effectiveness in improving positive, negative, and cognitive symptoms of schizophrenia while avoiding common side effects associated with traditional antipsychotics, such as weight gain and extrapyramidal symptoms [2]. - The inclusion of Nemonapride Chloride in the "Chinese Guidelines for the Prevention and Treatment of Schizophrenia (2025 Edition)" as an innovative therapy highlights its significance in clinical practice [2].